Partner Study Partners of people on ART: a New Evaluation of the Risks (PARTNER study)

Slides:



Advertisements
Similar presentations
Informed Consent and Patient Involvement in Trials Norbert Tamm Research Charge Nurse Imperial College & St. Mary’s Hospital London.
Advertisements

HIV/AIDS RISK FACTORS IN THE CONTEXT OF INCREASING ACCESS TO ENHANCED HIV/AIDS TREATMENT Stella Neema, PhD Department of Sociology Makerere University.
Unmet need for family planning and low rates of dual method protection among men and women attending HIV care and treatment services in Kenya, Namibia.
Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
HIV in the United Kingdom: 2013 HIV and AIDS Reporting Section Centre for Infectious Disease Surveillance and Control (CIDSC) Public Health England London,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.
A. D. Smith, 1 A. Muhaari 2 E. M. van der Elst 2 D. Kowuor, 2 A.Davies, 2 C Agwanda, 1 M. Price, 3 F. Priddy, 3 H. S. Okuku, 2 S.M. Graham, 4 E. J. Sanders.
Consistent and inconsistent use of HIV risk reduction strategies by Australian gay and bisexual men who report unprotected anal intercourse with casual.
Community HIV testing for men who have sex with men (MSM) Will it decrease undiagnosed infection? Jonathan Roberts Liaison Health Adviser Brighton & Sussex.
HIV INTERVENTION FOR PROVIDERS (HIP) Principal Investigators:  Carol Dawson Rose, RN, Ph.D. and Grant Colfax, MD. Co-Investigators:  Cynthia Gomez, Ph.D.,
Predictors of HIV Transmission Risk among Patients in Care: Results from the SPNS Prevention with Positives Initiative Stephen F. Morin, PhD Principal.
Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.
The Internet: An Emerging Venue for Syphilis Epidemics Among Men Who Have Sex with Men in Los Angeles LAC - DHS Getahun Aynalem, MD, MPH, Kellie Hawkins,
Testing history and risk behaviour of individuals requesting an HIV test through an online self-sampling service SJ Westrop 1, C James.
Nuanced seroadaptive behaviors among Seattle MSM: sexual decision- making based on ART use/viral load and recency of partner HIV testing Christine M. Khosropour,
Myths and Misconceptions
Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.
1 Joyce Abma and Gladys Martinez Adolescent Sexual Risk Behaviors and Reproductive Health: Data from the National Survey of Family Growth, 2002 National.
Racial Disparities in Antiretroviral Therapy Use and Viral Suppression among Sexually Active HIV-infected Men who have Sex with Men— United States, Medical.
Embedding Open-label PrEP trial in expansion of UK HIV Prevention Programme.
Effects of an HIV/AIDS peer prevention intervention on sexual and injecting risk behaviors among injecting drug users (IDUs) and their risk partners in.
Unit 5: Specialised Techniques: STI Prevalence Assessment and Combined STI/HIV Behavioural Surveillance Surveys #4-5-1.
Willingness to use HIV prevention strategies to conceive with an HIV-positive partner: opinions from HIV-negative women in serodifferent relationships.
Current European guidelines for management of arterial hypertension: Are they adequate for use in primary care? Halfdan Petursson Linn Getz Johann Agust.
EVENT LEVEL: Sex obtained through aggression will frequently be unprotected GLOBAL LEVEL: Men who have perpetrated sexual aggression will be more likely.
Focus Area 9 Family Planning Progress Review December 8, 2004.
Data Specifications Didactics on development of a concept sheet EA IeDEA Meeting May 16-17, 2011 Beverly Musick.
Tips for Researchers on Completing the Data Analysis Section of the IRB Application Don Allensworth-Davies, MSc Statistical Manager, Data Coordinating.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System HIV in the United Kingdom: 2012 Overview.
Sophia Osawe (BSc, AIMLS) Institute of Human Virology, Nigeria Nigerian Canadian Collaboration on AIDS Vaccines (NICCAV) Study Coordinator Discordant Couples.
Office of Global Health and HIV (OGHH) Office of Overseas Programming & Training Support (OPATS) Session: Voluntary Medical Male Circumcision (VMMC)
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
HIV and African M S M in England: A new wave of Challenge. Presented by Adebisi Alimi.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
The third international stroke trial (IST-3) effect of thrombolysis on outcomes at 18 months in 2348 patients in long-term follow- up cohort The IST3 collaborative.
HIV Care Continuum New Diagnoses, 2011, Fulton County, Georgia.
Bi- and Homosexuality in European sex surveys from the perspective of couple history Osmo Kontula, Ph.D.
Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.
Slide 1 Downloaded from Population Impact of Losartan Use on Stroke in the European Union (EU)
Martin Fisher Foundation: 14 September Remembering Martin Fisher Simon Collins, HIV i-Base Who should get tested? How and why should.
Drug users in Amsterdam: are they still at risk for HIV? Nienke van der Knaap, Bart Grady, Maarten Schim van der Loeff, Titia Heijman, Arjen Speksnijder,
1 MSM Sexual Health Summit August 20, 2012 HIV/STD Prevention and Care Branch Texas Department of State Health Services.
SEXUAL HEALTH: SCREENING, VACCINES AND REFERRALS Dr Kate Morton.
Audit of outcomes in HIV BHIVA Audit and Standards Sub-Committee E Ong (chair), J Anderson, D Churchill, M Desai, S Edwards, S Ellis, A Freedman, P Gupta,
Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,
Measuring Anal Intercourse in Vaginal Microbicide Studies/Trials
HIV Care Continuum New Diagnoses, 2011, Georgia. Persons with HIV Engaged in Selected Stages of the Continuum of Care, United States Percent
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
Ceri Evans Senior Sexual Health Adviser West London Centre for Sexual Health Chelsea and Westminster Hospital Foundation Trust.
XVII Annual International AIDS Conference SHAZ! Shaping the Health of Adolescents in Zimbabwe Mudekunye, S. Laver University of Zimbabwe-University of.
Paz Bailey G 1, Sternberg M 1, Puren AJ 2, Markowitz LE 1, Ballard R 1, Delany S 3, Hawkes S 4, Nwanyanwu O 1, Ryan C 1, and Lewis DA 5 1. NCHHSTP, CDC.
HIV Prevalence and Incidence Estimates Among Women with High Risk Indicators in Addis Ababa, Ethiopia Asfawesen G-Yohanes 1, Stephanie Combes 2, Abraham.
How much risky sex are people in Oregon with HIV having?
Associations Between Recent Gender- Based Violence and Pregnancy, Sexually Transmitted Infections, Condom Use Practices, and Negotiation of Sexual Practices.
Expanded PrEP implementation across Australia Expanded implementation of PrEP across Australia 1.
Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.
European-Comparative Effectiveness Research on online Depression Treatment E-COMPARED is funded by the European Community’s Seventh Framework.
On behalf of The MTN-020/ASPIRE Study Team
DISTRIBUTION AUTOMATIC - GENERATION
Identifying the Barriers of Condom Use in College Students Arielle Zimmer, RN State University of New York Institute of Technology Department of Nursing.
Cascade of care for persons newly diagnosed
MTN-025 (HOPE Study) Community Education Presentation
C-SCOPE: Survey on the Management of HCV in addiction clinics treating Patients on Opiate Agonist Therapies: a global perspective July 2017.
Overview.
Adolescents in Love: Mutuality of commitment in adolescent couples
HIV.
European Agency Statistics on Inclusive Education (EASIE) www
U=U Guidance for Implementation in Clinical Settings
Undetectable = Untransmittable
Presentation transcript:

Partner Study Partners of people on ART: a New Evaluation of the Risks (PARTNER study)

Study overview Funded by: The National Institute of Health Research (NIHR) in England Sponsored by: UCL – University College London Conducted by: UCL and CHIP - Copenhagen HIV programme

National Coordinators Dr Armin Rieger, Austria Prof Nathan Clumeck, Belgium Dr Lars Mathiesen, Denmark Dr Matti Ristola, Finland Dr Christian Pradier, France Dr Jan Van Lunzen, Germany Dr Gráinne Courtney, Ireland Prof Antonella d'Arminio Monforte, Italy Prof Francisco Antunes, Portugal Dr Vincente Estrada, Spain Dr Katarina Westling, Sweden Prof Pietro Vernazza, Switzerland Prof JM Prins, The Netherlands Dr Alison Rodger, UK Sites as of Sep. 2011: 65

The data that PARTNER study will provide HPTN 052 trial The trial clearly indicates that risk of transmission between serodifferent heterosexuals is very low when the seropositive patient is on ART. However we do not yet know how many couples used condoms consistently so we do not yet know from the trial (or from other studies) exactly what is the estimated transmission rate during unprotected sex Which is what we are studying in PARTNER. - It seems likely that based on the results of 052 more couples will have sex without condoms. - we urgently need more prospective observational data that will help to know exactly how low is the transmission risk under fully suppressive cART. In particular, we need data for gay men: we know transmission risks are different for anal sex.

PARTNER Aim 1. To study the risk of HIV transmission to HIV negative partners. Enrolled couples are partnerships that continue not to use condoms consistently and the HIV-positive partner is on therapy (with a viral load < 50 copies/mL) 2. To study why some partnerships do not use condoms. The study will also look at the proportion who begin to adopt consistent condom use, and factors associated with this. Objectives

Inclusion criteria for the sero-different pair On ART (regardless of viral load) Age > 18 Has an HIV negative partner Partners have had sex without condom (penetrative anal or vaginal intercourse) together in the past month Partners expect to have sex together again Blood sample from both partners in case of transmission Exclusion Pregnancy (only at enrolment)

Both partners will be seen at least every 4-6 months The HIV positive partner : can have the questionnaires given to them at their regular clinic follow up visit The HIV negative partner: min. 2 visit pr. year incl. HIV test and questionnaires The partners do not have to attend study visits together

Sample size Aim to recruit and follow sufficient number of partnerships in order to collect a total of 3,333 persons-years of prospective follow-up. Initially, 1650 partnerships will be identified, with the intention to follow them for 2 years. If for any reason a partnership chooses/is unable to contribute for the entire length of time, replacement will occur to achieve the overall target of 3,333 person-years. Anonymization of data Data on partnerships will be anonymized de-linked at intervals after the partnership is no longer under follow-up,including for partnerships where the HIV- person becomes infected. In such cases, virus from the HIV+ and (formerly) HIV-person will be compared after anonymization.

Analysis The primary analysis will be estimation of the rate of infection in partners per person year of unprotected sex partnership where the index patient has viral load <50 c/mL, excluding new infections that are shown to be phylogentically distinct from the HIV positive partner’s virus; i.e. transmission has not been from the HIV positive partner. This will be calculated as the number of infections identified at the end of eligible periods divided by the sum of the person time over eligible periods (see below for definition of eligible periods).

Case Report Forms (CRFs) Enrolment and Follow-up CRFs entered online

Example of enrolment CRF

Introducing the study to potential participants

Why is this study important? Even with recent studies on transmission (The Swiss statements 2008 and HPTN052, 2011) we are still lacking important information about HIV transmission risk Especially lacking is information about risk reduction in gay partnerships Lacking also information about condom use and sexual behaviour in relation to transmission risk The PARTNER study will attempt to answer these question to improve the information to HIV positive people and their sexual partners and, to improve treatment strategies

Strategies for enrolling pairs at site Start with asking if they have an HIV negative partner If yes, give a VERY short introduction to the PARTNER study and refer to the research nurses/staff It is recommended for the study nurse to inquire about sex without condom and other inclusion criteria. Some HIV positive people may not feel comfortable discussing this with their physician.

Presenting the study We are looking for sero-different couples The study aims are to understand transmission risk ART lowers the transmission risk We know that some sero-different pairs are not always having sex with condoms You have the opportunity to participate in the study at this clinic There are over 400 pairs currently enrolled Would you like to know more about the study?

Presenting the study Inclusion criteria: Do you have a negative partner? Provide them with the information pamphlet Has the couple had sex without a condom once in the last month? (If they forgot to use a condom, and occasionally forget, that also meets inclusion) Present the visit and the questionnaires Questionnaires are anonymous HIV positive partner does not have to come more than usual HIV negative partner needs to visit twice a year (or max 4 visits in 2 years)